Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings

Multiple sclerosis (MS) is a chronic autoimmune neurological disease that typically affects young adults, causing irreversible physical disability and cognitive impairment. Alemtuzumab, administered intravenously as 2 initial courses of 12 mg/day (5 consecutive days at baseline, and 3 consecutive da...

Descripción completa

Detalles Bibliográficos
Autores principales: Barclay, Krista, Carruthers, Robert, Traboulsee, Anthony, Bass, Ann D., LaGanke, Christopher, Bertolotto, Antonio, Boster, Aaron, Celius, Elisabeth G., de Seze, Jérôme, Cruz, Dionisio Dela, Habek, Mario, Lee, Jong-Mi, Limmroth, Volker, Meuth, Sven G., Oreja-Guevara, Celia, Pagnotta, Patricia, Vos, Cindy, Ziemssen, Tjalf, Baker, Darren P., Wijmeersch, Bart Van
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6439479/
https://www.ncbi.nlm.nih.gov/pubmed/30967831
http://dx.doi.org/10.3389/fneur.2019.00253

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6439479/
https://www.ncbi.nlm.nih.gov/pubmed/30967831
http://dx.doi.org/10.3389/fneur.2019.00253

Ejemplares similares